Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy.

In non-BVZ treated patients ( n = 224), HRs were not significant for cluster 3 (HR = 0.72, P = 0.18, CI 0.45–1.16 for PFS and HR = 0.84, CI 0.49–1.44 for OS, Cox regression), while for cluster 2 patients, a borderline significant effect was observed for PFS (HR = 0.57, P = 2.4 × 10 −2 , CI 0.35–0.93, Cox regression), which was not confirmed at the OS level (Supplementary Figure 8 ).

also in 11,409 other papers